218 related articles for article (PubMed ID: 25356039)
1. Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tract.
Pines M
World J Gastroenterol; 2014 Oct; 20(40):14778-86. PubMed ID: 25356039
[TBL] [Abstract][Full Text] [Related]
2. The role of halofuginone in fibrosis: more to be explored?
Luo Y; Xie X; Luo D; Wang Y; Gao Y
J Leukoc Biol; 2017 Dec; 102(6):1333-1345. PubMed ID: 28986385
[TBL] [Abstract][Full Text] [Related]
3. Halofuginone and muscular dystrophy.
Pines M; Halevy O
Histol Histopathol; 2011 Jan; 26(1):135-46. PubMed ID: 21117034
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.
Zion O; Genin O; Kawada N; Yoshizato K; Roffe S; Nagler A; Iovanna JL; Halevy O; Pines M
Pancreas; 2009 May; 38(4):427-35. PubMed ID: 19188864
[TBL] [Abstract][Full Text] [Related]
5. Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling.
Gnainsky Y; Kushnirsky Z; Bilu G; Hagai Y; Genina O; Volpin H; Bruck R; Spira G; Nagler A; Kawada N; Yoshizato K; Reinhardt DP; Libermann TA; Pines M
Cell Tissue Res; 2007 Apr; 328(1):153-66. PubMed ID: 17180598
[TBL] [Abstract][Full Text] [Related]
6. The effect of Halofuginone in the amelioration of radiation induced-lung fibrosis.
Yavas G; Calik M; Calik G; Yavas C; Ata O; Esme H
Med Hypotheses; 2013 Apr; 80(4):357-9. PubMed ID: 23352286
[TBL] [Abstract][Full Text] [Related]
7. Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases.
Lamora A; Mullard M; Amiaud J; Brion R; Heymann D; Redini F; Verrecchia F
Oncotarget; 2015 Jun; 6(16):14413-27. PubMed ID: 26015407
[TBL] [Abstract][Full Text] [Related]
8. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts.
McGaha TL; Phelps RG; Spiera H; Bona C
J Invest Dermatol; 2002 Mar; 118(3):461-70. PubMed ID: 11874485
[TBL] [Abstract][Full Text] [Related]
9. Halofuginone - the multifaceted molecule.
Pines M; Spector I
Molecules; 2015 Jan; 20(1):573-94. PubMed ID: 25569515
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone.
Halevy O; Genin O; Barzilai-Tutsch H; Pima Y; Levi O; Moshe I; Pines M
Histol Histopathol; 2013 Feb; 28(2):211-26. PubMed ID: 23275304
[TBL] [Abstract][Full Text] [Related]
11. Halofuginone ameliorates autoimmune arthritis in mice by regulating the balance between Th17 and Treg cells and inhibiting osteoclastogenesis.
Park MK; Park JS; Park EM; Lim MA; Kim SM; Lee DG; Baek SY; Yang EJ; Woo JW; Lee J; Kwok SK; Kim HY; Cho ML; Park SH
Arthritis Rheumatol; 2014 May; 66(5):1195-207. PubMed ID: 24782183
[TBL] [Abstract][Full Text] [Related]
12. Involvement of the tyrosine phosphatase early gene of liver regeneration (PRL-1) in cell cycle and in liver regeneration and fibrosis effect of halofuginone.
Gnainsky Y; Spira G; Paizi M; Bruck R; Nagler A; Genina O; Taub R; Halevy O; Pines M
Cell Tissue Res; 2006 Jun; 324(3):385-94. PubMed ID: 16508789
[TBL] [Abstract][Full Text] [Related]
13. Halofuginone improves muscle-cell survival in muscular dystrophies.
Bodanovsky A; Guttman N; Barzilai-Tutsch H; Genin O; Levy O; Pines M; Halevy O
Biochim Biophys Acta; 2014 Jul; 1843(7):1339-47. PubMed ID: 24703880
[TBL] [Abstract][Full Text] [Related]
14. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats.
Bruck R; Genina O; Aeed H; Alexiev R; Nagler A; Avni Y; Pines M
Hepatology; 2001 Feb; 33(2):379-86. PubMed ID: 11172339
[TBL] [Abstract][Full Text] [Related]
15. Halofuginone: a novel antifibrotic therapy.
Pines M; Nagler A
Gen Pharmacol; 1998 Apr; 30(4):445-50. PubMed ID: 9522159
[TBL] [Abstract][Full Text] [Related]
16. Halofuginone alleviates acute viral myocarditis in suckling BALB/c mice by inhibiting TGF-β1.
Sun XH; Fu J; Sun DQ
Biochem Biophys Res Commun; 2016 Apr; 473(2):558-64. PubMed ID: 27021682
[TBL] [Abstract][Full Text] [Related]
17. The role of TGF-beta in digestive organ disease.
Takenoshita S; Fukushima T; Kumamoto K; Iwadate M
J Gastroenterol; 2002; 37(12):991-9. PubMed ID: 12522529
[No Abstract] [Full Text] [Related]
18. The effect of antifibrotic drug halofugine on Th17 cells in concanavalin A-induced liver fibrosis.
Liang J; Zhang B; Shen RW; Liu JB; Gao MH; Geng X; Li Y; Li YY; Zhang W
Scand J Immunol; 2014 Mar; 79(3):163-72. PubMed ID: 24383550
[TBL] [Abstract][Full Text] [Related]
19. Fibrosis inhibition and muscle histopathology improvement in laminin-alpha2-deficient mice.
Nevo Y; Halevy O; Genin O; Moshe I; Turgeman T; Harel M; Biton E; Reif S; Pines M
Muscle Nerve; 2010 Aug; 42(2):218-29. PubMed ID: 20589893
[TBL] [Abstract][Full Text] [Related]
20. The preventive effect of halofuginone on posterior glottic stenosis in a rabbit model.
Yoon YH; Rha KS; Koo BS; Park JY; Kim YM; Park YH
Otolaryngol Head Neck Surg; 2008 Jul; 139(1):94-9. PubMed ID: 18585568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
